Slide 1: Zur Rose Group
ZurKose Group
Slide 2: 1st Half-Year Results 2022
1st Half-Year Results 2022 Webcast — Walter Hess and Marcel Ziwica
Slide 3: Group outlook / Key messages
Group outlook Key messages Zur Rose Group Hi results 2022
Slide 4: Agenda
Agenda Business update Break-even programme Financial update Outlook Q&A TR ON Zur Rose Group Hi results 2022
Slide 5: Business update
Business update
Slide 6: Business update
Business update − − − 1in local currency | 2vs. 2nd half-year 2021 | 3as of 30 June 2022
Slide 7: Milestone achieved: new distribution center Heerlen live
Business update Milestone achieved: new distribution center Heerlen live — Successful go live accomplished — Strategic milestone and precondition for brand integrations — Capacity increase from 12m to 27m parcels per year — Unique infrastructure with highly efficient and secured processes to fulfill
Slide 8: Integration of medpex brand to Heerlen started
Business update Integration of medpex brand to Heerlen started — Operational integration of medpex volume into new distribution center Heerlen — Closure of Stifts-Apotheke (medpex) in Ludwigshafen by owner 9 DocMorris end of October 2022 - about 350 employees concerned — Location Ludwigshafen will c
Slide 9: Mandatory eRx rollout timeline
Business update 1st Sep 2022 Dec 2022 Spring 2023 Mandatory eRx in Completion of Roll out in Schleswig- Schleswig-Holstein and nationwide roll out Holstein and Westphalia-Lippe2 including final nine Westphalia-Lippe states (11m inhabitants, Roll out in six 14% of population) additional states Succes
Slide 10: Business update
Business update − − − − − − − − − − 1https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/finanzergebnisse.html | 2gematik 2022 | 3Kantarstudie and YouGov BrandIndex 2022 (aided) | 4wissenschaftliches Institut der AOK 2020 | 5Sveriges Apote
Slide 11: Break-even programme
Break-even programme
Slide 12: EBITDA break-even 2023
Break-even programme EBITDA break-even 2023 2017 - 2021 2022 - 2023 2024+ Ce «Growth» «Break even» «Profitable growth» Growth of revenue and active cus Profitable eRx growth Investments in best talents, Beeansiontoneiertllnealthy ecosystem and finicommetitomel fcantion y' Profitable double digit gro
Slide 13: Accelerated break-even programme
Break-even programme Accelerated break-even programme with expected positive EBITDA impact of CHF 130m vs. EBITDA 2021 by 2023 — Accelerated execution is expected to lead to EBITDA break-even in 2023 — Realisation of full year effects in 2023 requires immediate implementation of measures with mid- s
Slide 14: Break-even programme
Break-even programme − − − − − − − − − −
Slide 15: Expected free cash flow
Break-even programme Expected free cash flow1 − 2021 2022 2023 2024 − (200) − − 1Refers to cash flow pre financing activities (figures rounded)
Slide 16: Financial update
Financial update
Slide 17: Financial update: revenue by region
Financial update in CHF m +0.4%1 +9.6% +2.9%1 -3.9%1 998.02 963.92 H1 2021 Switzerland Germany Europe H1 2022 external revenue3 external revenue3 external revenue3 Notes: 1in local currency | 2including eliminations of CHF 3.6m for H1 2021 and CHF 3.8m for H1 2022 | 3consolidated revenue of the Zur
Slide 18: Active customers, repeat order rate, site visits
Financial update Active customers1 Repeat order rate2 Site visits3 in m FY 2020 H1 2021 FY 2021 H1 2022 FY 2020 H1 2021 FY 2021 H1 2022 Basket size4 Order frequency5 in EUR Rx OTC 11.7 12.4 11.7 10.5 122 117 128 115 4.2 4.0 3.7 3.9 41 40 39 39 2.1 2.0 2.1 2.1 FY 2020 H1 2021 FY 2021 H1 2022 FY 2020
Slide 19: Adjusted EBITDA development
Financial update in CHF m H1 2021 H2 2021 H1 2022 adj. adj. adj. EBITDA EBITDA EBITDA eRx readiness Cost & marketing Reduced reduction and growth efficiency (20.0) International expenses (42.9) expansion (49.2) International 5.9 2.3 eRx expansion Increased marketing 11.4 (12.6) growth expenses 17.2
Slide 20: H1 2022 income statement
Financial update H1 2022 Margin H2 2021 Margin H1 2021 Margin in CHF m in % in % in % External revenue 963.9 1036.0 998.0 Consolidated revenue 824.0 886.7 839.8 Gross profit adj. 121.6 14.8 126.1 14.2 136.9 16.3 Personnel expenses adj. (77.4) (9.4) (69.9) (7.9) (73.2) (8.7) Marketing expenses (38.0)
Slide 21: EBITDA adjustments
Financial update H1 2021 H1 2022 EBITDA adjustments Adj. EBITDA adjustments Adj. EBITDA EBITDA in CHF m in CHF m M&A Integration Other M&A 0.7 (42.9) Integration Other 1.2 (43.1) (49.7) 5.0 (49.2) 0.9 (12.0) 5.0
Slide 22: Balance sheet and cash
Financial update 30 June 2022 % 31 Dec 2021 % in CHF m Cash and cash equivalents 199.2 277.7 Receivables 162.5 166.5 Inventories 70.4 92.5 Property, plant & equipment 96.4 98.7 Intangible assets 580.8 595.4 Other assets 34.5 38.4 Total assets 1143.8 1269.2 Financial liabilities 67.1 83.8 Payables &
Slide 23: Outlook
Outlook ‘Zur Rose Group Hi results 2022 23
Slide 24: Group outlook
Group outlook EBITDA guidance confirmed despite reduced revenue External revenue 2022 in local currency Revenue OTC DocMorris 2022 adj. EBITDA 2022 adj. EBITDA break-even adj. EBITDA margin mid-term Zur Rose Group mid-single digit decline (due to focus on earlier EBITDA break-even) Previously: flat
Slide 25: Key takeaways
Key takeaways Zur Rose Group Hi results 2022
Slide 26: Q&A
Q&A ‘Zur Rose Group Hi results 2022 26
Slide 27: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Zur Rose Group AG ("Zur Rose" and together with its subsidiaries, "we", "us" or the "Group") solely for informational purposes and has not been independently verified and no representation or warranty, express or implied, is made